Seminars in Oncology
Volume 35 , Pages S13-S21 , June 2008

Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies

  • Diane Braguer

      Affiliations

    • INSERM UMR911, Centre de Recherche en Oncologie Biologique, et Oncopharmacologie; Aix-Marseille University, Marseille, France.
    • Corresponding Author InformationAddress correspondence to Diane Braguer, PhD, Faculte de Pharmacié, INSERM UMR 911, 27 Boulevard Jean Moulin, 13005 Marseille, France.
    • ,
  • Jean-Marc Barret

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.
    • ,
  • Hayley McDaid

      Affiliations

    • Albert Einstein College of Medicine, Bronx, NY.
    • ,
  • Anna Kruczynski

      Affiliations

    • Centre de Recherche d'Oncologie Expérimentale, Institut de Recherche Pierre Fabre, Toulouse, France.

References 

  1. Kruczynski A, Colpaert F, Tarayre JP, Mouillard P, Fahy J, Hill BT. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol. 1998;41:437–447
  2. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989;16(Suppl 4):15–20
  3. Hill BT, Fiebig HH, Waud WR, Poupon MF, Colpaert F, Kruczynski A. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer. 1999;35:512–520
  4. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development (A review of its preclinical anticancer properties). Crit Rev Oncol Hematol. 2001;40:159–173
  5. Bonfil RD, Russo DM, Binda MM, Delgado FM, Vincenti M. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol. 2002;7:159–166
  6. Kruczynski A, Barret JM, Etievant C, Colpaert F, Fahy J, Hill BT. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol. 1998;55:635–648
  7. Okouneva T, Hill BT, Wilson L, Jordan MA. The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics. Mol Cancer Ther. 2003;2:427–436
  8. Pourroy B, Carre M, Honore S, Bourgarel-Rey V, Kruczynski A, Briand C, et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol. 2004;66:580–591
  9. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol. 1998;18:3509–3517
  10. Toh HC, Sun L, Koh CH, Aw SE. Vinorelbine induces apoptosis and caspase-3 (CPP32) expression in leukemia and lymphoma cells: a comparison with vincristine. Leuk Lymphoma. 1998;31:195–208
  11. Wyllie AH. Apoptosis: an overview. Br Med Bull. 1997;53:451–465
  12. Miller DK. The role of the Caspase family of cysteine proteases in apoptosis. Semin Immunol. 1997;9:35–49
  13. Esteve MA, Carré M, Braguer D. Microtubules in apoptosis induction: Are they necessary?. Curr Cancer Drug Targets. 2007;7:325–334
  14. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44:355–361
  15. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res. 2000;254:110–119
  16. Kruczynski A, Etievant C, Perrin D, Chansard N, Duflos A, Hill BT. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer. 2002;86:143–150
  17. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem. 1998;273:4928–4936
  18. Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, et al. Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine. Mol Cancer Ther. 2006;5:2824–2833
  19. Taraboletti G, Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol. 2001;1:378–384
  20. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974
  21. Pasquier E, Honoré S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand?. Drug Resist Updat. 2006;9:74–86
  22. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143–4155
  23. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843–1849
  24. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C, et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res. 2005;65:2433–2440
  25. Pourroy B, Honoré S, Pasquier E, Bourgarel-Rey V, Kruczynski A, Briand C, et al. Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells. Cancer Res. 2006;66:3256–3263
  26. Kruczynski A, Poli M, Dossi R, Chazottes E, Berrichon G, Ricome C, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006;42:2821–2832
  27. Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer. 2001;84:290–295
  28. Barret JM, Etievant C, Hill BT. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol. 2000;45:471–476
  29. Ramlau R, Souquet P, Sun X, et al. Results of a phase I/II and pharmacokinetic study of vinflunine VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). [abstract 7110] J Clin Oncol (Meeting Abstracts). 2004;22(14S):643s
  30. Souquet P, Ramlau R, Sun X, et al. Vinflunine (VFL) and cisplatin (CDDP) combination in first line treatment of advanced non-small-cell lung cancer (NSCLC). Final results of a phase II study. Paper presented at the World Conference on Lung Cancer; July 3, 2005; Barcelona, Spain. Poster 571.
  31. Lemarie E, Bennouna J, Grossi F, et al. Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (ptd): preliminary results of the phase I and pharmacokinetic study. [abstract 7266] J Clin Oncol. 2005;23(16S):686s
  32. Tourani J, Pinel M, Planchard D, Aslanis V, Gouva S, Robinet G. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): final results. [abstract 7271] J Clin Oncol. 2005;23(16S):688s
  33. Campone M, Fumoleau P, Roche H, Bonneterre J, et al. A dose-finding and pharmacokinetic study of IV vinflunine (VFL) in combination with capecitabine (CAPE) as second line treatment of metastatic breast cancer (MBC). Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, TX.
  34. Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2 (Current status and future perspective). Front Biosci. 2005;10:1415–1439
  35. Reid A, Vidal L, Shaw H, de BJ. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 2007;43:481–489
  36. Peacock NW, Spigel DR, Mainwaring PN, et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer. [abstract 1043] J Clin Oncol. 2007;28(18S):42s
  37. Paridaens R, Wildiers H, et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. Chicago, IL: American Society of Clinical Oncology; 2007;
  38. Catalogue of Somatic Mutations in Cancer. http://www.sanger.ac.uk/perl/genetics/CGP/cosmic(Accessed Dec 19, 2007)
  39. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007;25:581–593
  40. Simoens C, Vermorken JB, Korst AE, et al. Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol. 2006;58:210–218
  41. Simoens C, Pauwels B, Vermorken JB, Patyn GG, Lambreckts HA, Breillout F, et al. Further mechanistic unraveling of the influence of the cell cycle effects on the radiosensitising mechanism of vinflunine, in vitro. Cancer Chemother Pharmacol. 2008;In press
  42. Venditti JM. Preclinical drug development: Rationale and methods. Semin Oncol. 1981;8:349–361

 Dr Braguer has no conflict of interest to declare. Dr McDaid has served as a consultant to Bristol-Myers Squibb. Drs Kruczynski and Barret are employees of the Institut de Recherche Pierre Fabre, a private pharmaceutical company supporting the development of vinflunine.

PII: S0093-7754(08)00023-7

doi: 10.1053/j.seminoncol.2008.01.011

Seminars in Oncology
Volume 35 , Pages S13-S21 , June 2008

Article Tools

* Image Usage & Resolution